Healthcare entity
All 2 tracked stories fall under one category: market-trends. Freightos is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 13-day window averages about 1.1 stories each week. Each story carries 2.5 original sources on average, compared with 3.4 for the broader beat in this window.
Last mentioned: Mar 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: market-trends. Freightos is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 13-day window averages about 1.1 stories each week. Each story carries 2.5 original sources on average, compared with 3.4 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. This profile follows 2 Healthcare stories mentioning PepGen across the period from February 21, 2026 to March 5, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 218 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering PepGen. Shared-story counts are live from our verified record — not editorial picks.
Earnings Release
Both companies report Q4 and FY 2025 financial results and business highlights.
FDA Partial Hold
FDA notifies PepGen of partial clinical hold on Freedom2 trial.
Fiscal Year End
OmniAb and PepGen conclude their 2025 fiscal years.
OmniAb and PepGen reported full-year 2025 results, highlighting a divergence between platform-based stability and clinical-stage volatility. While OmniAb expanded its royalty-bearing portfolio, PepGen faced a significant setback with a partial FDA clinical hold on its Freedom2 trial.
Source: pharmiweb.com · pharmiweb.com
GeneDx and PepGen are scheduled to report quarterly financial results on Monday, marking a pivotal moment for the genomic diagnostics and neuromuscular biotech sectors. Investors are looking for GeneDx's continued path toward profitability through whole genome sequencing and PepGen's clinical pipeline progress.
PepGen is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
